Acute radiation syndrome (ARS) results from high-dose ionizing radiation (IR) exposure, with bone marrow (BM) being highly susceptible due to its proliferative activity. BM injury causes pancytopenia, leading to infections, anemia, and bleeding. Mesenchymal stem cells (MSCs) hold promise for ARS treatment because of their immunomodulatory, anti-inflammatory, and regenerative properties. However, challenges such as replicative senescence, poor survival, and engraftment in irradiated microenvironments limit their efficacy. This study evaluated rapamycin-preconditioned placenta-derived MSCs (rPD-MSCs) in a mouse ARS model. Rapamycin was selected for preconditioning due to its ability to induce autophagy and modulate cytokine secretion. We assessed rapamycin-dependent modulation of autophagy-related genes and proteins, as well as hematopoietic cytokines secretion in PD-MSCs, and evaluated morphological changes in blood and BM at 7 and 21 days post-irradiation in ICR/CD1 mice. Preconditioning with rapamycin alters the secretion of granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF), and Fms-related tyrosine kinase 3 ligand (Flt3LG) in PD-MSCs without affecting cell viability. rPD-MSCs better enhance hematopoietic recovery, restore bone marrow cellularity, and increase peripheral blood cell counts by elevating the secretion of hematopoietic cytokines compared to non-preconditioned cells. These results highlight rapamycin preconditioning as a promising strategy to enhance MSCs therapeutic potential for ARS, supporting further preclinical and clinical exploration.
Introduction. Acute radiation disease is one of the urgent problems of modern medicine. The new approach using mesenchymal stem cells (MSCs) show its effectiveness. Results of MSC therapy is contradictory and requires further researches to assess the production of hematopoiesis-inducing growth factors and the level of hematopoiesis activation.The purpose of the study was modeling of autophagy process with estimation of the degree of hematopoiesis restoration using modulated MSCs.Materials and methods. The experiment was carried out on 60 outbred mice. Animals were exposed to ionizing radiation (IR) with transplantation of modulated and unmodulated MSCs to analyze reticulocyte, leukocyte formula, bone marrow with myelogram counting and enzyme immunoassay. Statistical analysis was performed using IBM SPSS Statistics 27 program.Results and discussion. After IR exposure, a decreased in lymphoid (–45.0 %), neutrophilic (–19.5 %) and megakaryocyte lineages (–52.2 %) was noted. Expression of SCF and Flt3-ligand was higher in the MSC + trehalose group compared to rapamycin by 16.3 % and 19.7 %. Using MSCs increased bone marrow cellularity by +11.1 % due to neutrophilic and lymphoid cells. MSC with activated mTOR-independent autophagy increased in bone marrow cellularity among the studied groups: lymphocytes +12.9 %, megakaryocytes +15.2 %. Inhibition of autophagy in MSC decreased numbers of myelokaryocytes (–8.7 %), neutrophilic (–14.5 %) and lymphoid (–9.8 %) cells.Conclusion. The use of MSCs with activated mTOR-independent autophagy has a greater therapeutic potential in the restoration of hematopoiesis. Inhibition of autophagy in MSCs worsens their biological properties in terms of growth factor production and myeloid tissue regeneration after IR exposure.
BACKGROUND: Myeloid tissue is among the most radiosensitive tissues and represents one of the first structures to be affected by ionizing radiation exposure. Damage to myeloid tissue manifests as suppression of hematopoiesis, depletion of the hematopoietic stem cell pool, and impairment of bone marrow stromal components. One promising approach for hematopoietic recovery in acute radiation syndrome involves multipotent mesenchymal stromal cells (MMSCs). Their ability to form a “niche” for hematopoietic stem cells, secrete hematopoietic factors, and exert immunosuppressive effects allows MMSCs to be considered an effective tool of cellular therapy, particularly in allogeneic transplantation. However, the efficacy of MMSCs is limited by their low viability and functional activity post-transplantation. Therefore, enhancing the regenerative potential of MMSCs represents a key challenge. One potential approach to address this issue may involve modulation of autophagy in MMSCs. AIM: To investigate the effects of autophagy modulation in MMSCs on their functional activity and ability to stimulate myeloid tissue regeneration in a model of acute radiation syndrome. METHODS: MMSCs were isolated from the chorion of ICR (CD1) mouse placentas and cultured with autophagy activator sirolimus and autophagy inhibitor 3-methyladenine. In vitro assessments included cell viability, concentrations of autophagy proteins (Beclin-1 and LC3B), and secretion of hematopoietic growth factors: SCF (stem cell factor), G-CSF (granulocyte colony-stimulating factor), and FLT3 ligand (Fms-related tyrosine kinase 3 ligand). In vivo experiments involved modeling acute radiation syndrome followed by MMSCs transplantation into laboratory animals. Bone marrow analysis and blood parameters were evaluated on day 7 post-irradiation. RESULTS: Autophagy activation with sirolimus increased concentrations of hematopoietic growth factors: SCF by 70.5%, G-CSF by 59.6%, and FLT3 ligand by 62.3% (p ≤ 0.0001). Transplantation of MMSCs with activated autophagy promoted a more pronounced increase in cellularity within granulocytic (+4.5%, p = 0.026), lymphocytic (+18.8%, p 0.0001), and megakaryocytic (+30.5%, p = 0.011) lineages. Autophagy inhibition reduced growth factor secretion and abolished the therapeutic effect of MMSCs. CONCLUSION: Autophagy activation in MMSCs represents a promising approach for hematopoietic recovery in acute radiation syndrome models.
Restoring damaged tissues and organs, particularly in cases of acute radiation injury, remains one of the major challenges in regenerative medicine. Acute radiation syndrome caused by high-dose ionizing radiation exposure is associated with profound suppression of hematopoiesis and damage to the bone marrow stroma. Multipotent mesenchymal stromal cells are regarded as a promising therapeutic tool because of their differentiation potential, immunomodulatory properties, secretion of trophic factors, and ability to support the hematopoietic niche. However, their clinical efficacy is limited by low survival under conditions of oxidative stress and inflammation. Mechanisms that increase the resistance of multipotent mesenchymal stromal cells to damaging factors and enhance their regenerative potential remain insufficiently studied. This work reviews current data on the role of autophagy—an evolutionarily conserved process of intracellular renewal—as a potential approach to increasing the functional activity of multipotent mesenchymal stromal cells. Pharmacologic strategies for autophagy modulation are discussed, including mTOR-dependent (sirolimus) and mTOR-independent (lithium, trehalose) approaches, as well as their effects on the survival, migration, and secretory activity of multipotent mesenchymal stromal cells. Particular attention is given to cell preconditioning as a strategy to enhance therapeutic efficacy in radiation injury. Available evidence supports the use of targeted autophagy activation as a key component in the development of standardized next-generation cell-based products capable of not only supporting but also actively restoring hematopoiesis after acute radiation exposure.